Shanghai Junshi Biosciences (OTCPK:SHJB.F) - Aandelenkoers, Nieuws & Analyse

SHJB.F Overzicht aandelen

Shanghai Junshi Biosciences Co., Ltd., een biofarmaceutisch bedrijf, houdt zich bezig met het ontdekken, ontwikkelen en op de markt brengen van verschillende geneesmiddelen in de therapeutische gebieden oncologie, metabolisme, auto-immuunziekten, neurologische ziekten, zenuwstelsel en infectieziekten in de Volksrepubliek China. Meer informatie

SHJB.F fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 29.55% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Shanghai Junshi Biosciences Co., Ltd. Concurrenten

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.1b

Xencor

NasdaqGM:XNCR

US$1.8b

NewAmsterdam Pharma

NasdaqGM:NAMS

US$1.9b

Dynavax Technologies

NasdaqGS:DVAX

US$1.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Shanghai Junshi Biosciences
Historische aandelenkoersen
Huidige aandelenkoers	HK$1.24
52 Week Hoogtepunt	HK$2.06
52 Week Laag	HK$0.95
Bèta	0.41
11 maand verandering	0%
3 maanden verandering	-17.33%
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-89.17%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	SHJB.F	US Biotechs	US Markt
7D	0%	2.5%	2.2%
1Y	n/a	16.1%	31.6%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe SHJB.F presteerde ten opzichte van de US Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe SHJB.F presteerde ten opzichte van de US markt.

Prijsvolatiliteit

Is SHJB.F's price volatile compared to industry and market?
SHJB.F volatility
SHJB.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SHJB.F is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van SHJB.F in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	2,532	Cong Li	www.junshipharma.com

Shanghai Junshi Biosciences Co, Ltd, een biofarmaceutisch bedrijf, houdt zich bezig met het ontdekken, ontwikkelen en op de markt brengen van verschillende geneesmiddelen in de therapeutische gebieden oncologie, metabolisme, auto-immuunziekten, neurologische ziekten, zenuwstelsel en infectieziekten in de Volksrepubliek China. Het bedrijf werd opgericht in 2012 en heeft zijn hoofdkantoor in Shanghai, Volksrepubliek China.

Shanghai Junshi Biosciences Co., Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Shanghai Junshi Biosciences zich tot de beurswaarde?
SHJB.F fundamentele statistieken
Marktkapitalisatie	US$3.43b
Inkomsten(TTM)	-US$248.90m
Inkomsten(TTM)	US$246.68m

6.3x

P/S-verhouding

-6.3x

Koers/Winstverhouding

Is SHJB.F overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SHJB.F resultatenrekening (TTM)
Inkomsten	CN¥1.79b
Kosten van inkomsten	CN¥622.89m
Brutowinst	CN¥1.16b
Overige uitgaven	CN¥2.97b
Inkomsten	-CN¥1.80b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.83
Brutomarge	65.15%
Nettowinstmarge	-100.90%
Schuld/Eigen Vermogen Verhouding	43.8%

Hoe presteerde SHJB.F op de lange termijn?

Bekijk historische prestaties en vergelijking

SHJB.F Overzicht aandelen

Beloningen

Risicoanalyse

Shanghai Junshi Biosciences Co., Ltd. Concurrenten

NasdaqGM:CRSP

US$4.1b

NasdaqGM:XNCR

US$1.8b

NasdaqGM:NAMS

US$1.9b

NasdaqGS:DVAX

US$1.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets

Recent updates

Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets

Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022